Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
Fig 2
Recurrence free survival of patients with CDK4, MDM2 and p53 expression or TP53 mutated tumors.
Kaplan-Meier survival curve showing analysis of recurrence free survival in patients from the SSGXVIII study. A high expression of CDK4 is positively correlated with recurrence free survival (red line, p = 0.01) in contrast to a high expression of MDM2 and p53 (TP53, red line, p = 0.06 and p = 0.01, respectively, log-rank test). TP53 mutations tend to correlate to a worse recurrence free survival but did not reach significant levels due to a small number of mutated tumors (p = 0.24, log-rank test).